NCT06689540 (MTS105 for HCC) is a Phase 1 clinical trial of MTS105 in Liver Cancer, Adult, sponsored by Shen Lin.

Who is sponsoring NCT06689540?

NCT06689540 is sponsored by Shen Lin.

What drugs are being tested in NCT06689540?

Interventions in NCT06689540: MTS105.

What condition does NCT06689540 study?

NCT06689540 studies Liver Cancer, Adult, Metastatic Liver Cancers, HCC - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC).

Is NCT06689540 still recruiting?

NCT06689540 is currently recruiting now. Last updated 24 December 2024.

Last reviewed 2024-12-24 · How we verify

NCT06689540: MTS105 for HCC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mts105 for Advanced Hepatocellular Carcinoma

Recruiting now Phase 1 Last updated 24 December 2024

What this trial tests

Phase 1 trial testing MTS105 in Liver Cancer, Adult in 14 participants. Currently enrolling.

Timeline

18 November 2024

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	Shen Lin
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	18 November 2024
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

MTS105 — full drug profile →

Conditions studied

Liver Cancer, Adult — all drugs for Liver Cancer, Adult →
Metastatic Liver Cancers — all drugs for Metastatic Liver Cancers →
HCC - Hepatocellular Carcinoma — all drugs for HCC - Hepatocellular Carcinoma →
Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →

Sponsor

Shen Lin — full company profile →

Who can join

18 and older, any sex, with Liver Cancer, Adult or Metastatic Liver Cancers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Applications of mRNA Delivery in Cancer Immunotherapy.
Pan X, Zhang YW, Dai C, Zhang J, et al · · 2025 · cited 11× · PMID 40125430 · DOI 10.2147/ijn.s500520
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.
Zhang J, Li R, Tan X, Wang C. · · 2025 · cited 9× · PMID 40862283 · DOI 10.14218/jcth.2025.00099
Therapeutic mRNA vaccine applications in oncology.
Elliott L, Foster T, Castillo P, Mendez-Gomez H, et al · · 2025 · cited 4× · PMID 40336197 · DOI 10.1016/j.ymthe.2025.04.044
Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma.
Yu X, Zhang Q, Wang L, Zhang Y, et al · · 2025 · cited 4× · PMID 40307921 · DOI 10.1186/s40164-025-00658-z
Organ-specific delivery of an mRNA-encoded bispecific T cell engager targeting glypican-3 in hepatocellular carcinoma.
Huang Y, Liu S, Zhang X, Zhang B, et al · · 2025 · cited 1× · PMID 41397962 · DOI 10.1038/s41467-025-66087-y
The Immune Microenvironment in Liver Cancer: From Analysis to Targeting.
Lan J, Li H, Xue J, Duan Y, et al · · 2025 · cited 1× · PMID 41201063 · DOI 10.1002/advs.202518487
Advances in delivery technologies-powered cancer vaccines.
Huang C, Wang H, Luo S, Yu C, et al · · 2026 · PMID 41756688 · DOI 10.1016/j.bioactmat.2026.02.014

Verify or expand the search:

Other recruiting trials for Liver Cancer, Adult

Currently open trials in the same condition.

NCT07295262 — NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC · EARLY_PHASE1 · recruiting
NCT07315633 — An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies fo · recruiting
NCT07345247 — RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study · recruiting
NCT07070362 — Digital Early Warning System for Acute Lung Injury in Liver Surgery · recruiting
NCT06777628 — Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma · recruiting

Other Shen Lin trials

Trials by the same sponsor.

NCT05638828 — A Study of RD14-01 in Patients With Advanced Solid Tumors · EARLY_PHASE1 · unknown
NCT04640103 — An Observational Study of Perioperative Immunotherapy in MSI-H Gastrointestinal Tumors · unknown
NCT04993378 — Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06689540 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shen Lin
Last refreshed: 24 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06689540.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing